This report was first published by Endpoints News. To see the original version, click here
Oricell Therapeutics has raised more than $110 million in what it calls a pre-IPO financing. The company is developing CAR-T therapies for solid tumors, including a GPC3-targeted autologous CAR-T therapy for a type of liver cancer.
The new close announced Friday adds at least $40 million to the $70 million the Shanghai-based biotech raised in January. The round was led by investors including Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, and an unnamed “leading global healthcare fund.” An unspecified international sovereign wealth fund also participated.
您已阅读23%（699字），剩余77%（2320字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。